Monitoring and Analysis of Chinese Chronic Myeloid Leukemia Patients Who Have Stopped Tyro

Monitoring and Analysis of Chinese Chronic Myeloid Leukemia Patients Who Have Stopped

Tyrosine Kinase Inhibitor Therapy

Na SHEN[1];Yong YOU[1];Zhao-dong ZHONG[1];Li MENG[2];Jian-feng ZHOU[2];Ping ZOU[1];Xiao-jian ZHU[2];Hong-xiang WANG[3];Fan-jun CHENG[1];

【期刊名称】《当代医学科学(英文)》 【年(卷),期】2019(039)002

【摘要】Discontinuation of tyrosine kinase inhibitor(TKI)therapy after achieving a persistent deep molecular response(DMR)is an urgently needed treatment goal for chronic myeloid leukemia(CML)patients and has

been

included

in

the

National

Comprehensive

Cancer

Network(NCCN)guidelines(version 2.2017)for CML.Indeed,various

studies have confirmed the feasibility of discontinuing TKI therapy.In this study,we analyzed data from 45 CML patients who had discontinued TKI therapy.Univariate analysis was performed to predict factors

that

were

potentially

related

to

treatment-free

remission(TFR)and identify the differences between early relapse and late relapse.Out of the 45 patients,20 exhibited molecular relapse after a median follow-up of 18 months(range,1-54 months),and the estimated TFR at 24 months was 40%.The univariate analysis revealed that a high Sokal score and interruptions or dose reductions during TKI treatment were the only baseline factors associated with poor outcomes.Our